A pill for infertility: Oxolife’s non-hormonal oral drug raises embryo implantation rate, pregnancy rates and live birth rate in women undergoing IVF and ICSI, data being presented at ESHRE shows
A pill for infertility: Oxolife’s non-hormonal oral drug raises embryo implantation rate, pregnancy rates and live birth rate in women undergoing IVF and ICSI, data being presented at ESHRE shows Barcelona, Spain – 8 July 2024: Oxolife, the female fertility biotech focused on enhancing embryo implantation in women undergoing assisted reproductive technology (ART) fertility treatment, […]
OXOART2, selected as one of the most exciting pieces of research presented at ESHRE 40th annual meeting celebrated in Amsterdam
Novel treatment improves embryo implantation and live birth rates in infertile women undergoing IVF and ICSI New research has demonstrated the effectiveness of a first-in-class oral, non-hormonal drug in increasing embryo implantation, pregnancy and live birth rates among infertile women who are undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) [1]. The findings, […]
Oxolife will present the first OXO-001 results at the European Congress of Human Reproduction (ESHRE)
OXOLIFE is thrilled to announce that on Monday, July the 8th, our CEO, Agnès Arbat Arbat, will be presenting the abstract “Efficacy results from the phase II randomized clinical trial: OXO-001 in infertile women undergoing egg donation IVF/ICSI” at the 40th Annual European Society of Human Reproduction and Embryology (ESHRE) Meeting, in Amsterdam . This presentation has been selected as one of the […]
Oxolife Appoints International Fertility Experts to its Scientific Advisory Board
Barcelona, Spain – 13th November 2023, Oxolife, the specialist biotech focused on enhancing embryo implantation in women undergoing Assisted Reproductive Technology (ART) fertility treatment, today announces it has appointed globally renowned fertility experts to its Scientific Advisory Board (SAB). There is a very large and growing global infertility market, with 76m women a year affected […]
OXO-001, for embryo implantation makes headlines in the Daily News!
Oxolife and its phase II asset OXO-001 for embryo implantation have been featured in the UK’s highest circulated daily newspaper. The Daily Mail calls the endometrium effect of OXO-001 “building a better womb lining nest” which translates into more live birth rates by providing the embryo with the right environment to progress. Link Daily News
Oxolife in the radio
We are delighted to share the interview to our CEO Agnès Arbat on #Lideratges, Ariadna’s Belver Comin program, where they have given voice to women who have entrepreneurial projects. 📢📢 During the interview, OXOLIFE origins were presented, how Agnès and Ignasi Canals started from zero and then, thanks to loans such as Enisa, the start-up […]
At OXOLIFE we are celebrating!!
After a year since the start of our clinical trial and after the last milestone of end of recruitment, we want to share with you the great news of the first births in OXOART2. We are VERY happy for the 9 families of the babies who have been born in the 3 countries participating in […]
Oxolife attend to ESHRE Congress 2022
These days the OXOLIFE team is in Milan (Italy) at European Society of Human Reproduction and Embryology (ESHRE) Congress, an important event in the field of assisted reproduction where thousands of professionals in this field attend to present and learn about the new advances of the ART We are committed to being able to help […]
At @OXOLIFE we are celebrating!
After 9 months of recruiting women who are looking for pregnancy, we have finally passed our milestone with 403 patients screened and 356 randomized in the #OXOART2 study! There is still work to be done in this #clinicaltrial but we want to thank all the patients and centres in Spain (@IVI RMA GLOBAL (Mallorca, Valencia, […]
Oxolife in the News
Our CEO Agnes Arbat is interviewed at IB radio to talk about our OXOART2 Clinical trial. She explains the potential of OXO-001 as a treatment for female infertility and which women can participate in this study in leading centers such as IVI RMA GLOBAL (Mallorca, Valencia, Madrid, Barcelona, Sevilla, Bilbao, Zaragoza), Ginemed (Sevilla), Quirónsalud (Barcelona, Madrid), Dexeus mujer (Barcelona), Fertty (Barcelona), Instituto Bernabeu (Madrid, Alicante) y Clínica Ginefiv (Madrid). […]